iBio

iBio develops next-generation cardiometabolic and obesity therapeutics designed to promote higher-quality weight loss by preserving and building muscle, improving metabolic function, and supporting long-term treatment through more convenient dosing and enhanced tolerability, while complementing existing therapies. The company also advances a precli... nical immuno-oncology pipeline targeting hard-to-treat solid tumors, including those in the breast, lung, and colorectal regions, as well as pancreatic cancer and glioblastoma. Its work is powered by a machine-learningdriven antibody discovery platform that provides core services such as precision epitope engineering, access to a proprietary fully human antibody library, antibody optimization through its StableHu technology, next-generation bispecific design via its EngageTx T-cell engager panel, and enhanced safety and developability through its ShieldTx masking system. The company is led by Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer.Read More